Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2‐CDG
Human Mutation · 2024-01 · 2024 (1)
DOI: 10.1155/2024/8813121 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Human Mutation, online erschienen am 03.10.2024. Verfasst von Sander Pajusalu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Genetics and Personalized Medicine Clinic, Tartu University Hospital, L. Puusepa Street 2, Tartu, Estonia. Hauptthemen laut MEDLINE: Congenital Disorders of Glycosylation, Genetic Association Studies, Phosphotransferases (Phosphomutases). Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, European Regional Development Fund, Eesti Teadusagentuur.
Abstract (Originalsprache)
We report on the largest single dataset of patients with PMM2‐CDG enrolled in an ongoing international, multicenter natural history study collecting genetic, clinical, and biological information to evaluate similarities with previous studies, report on novel findings, and, additionally, examine potential genotype/phenotype correlations. A total of 137 participants had complete genotype information, representing 60 unique variants, of which the most common were found to be p.Arg141His in 58.4% ( n = 80) of participants, followed by p.Pro113Leu (21.2%, n = 29), and p.Phe119Leu (12.4%, n = 17), consistent with previous studies. Interestingly, six new variants were reported, comprised of five missense variants (p.Pro20Leu, p.Tyr64Ser, p.Phe68Cys, p.Tyr76His, and p.Arg238His) and one frameshift (c.696del p.Ala233Argfs∗100). Patient phenotypes were characterized via the Nijmegen Progression CDG Rating Scale (NPCRS), together with biochemical parameters, the most consistently dysregulated of which were coagulation factors, specifically antithrombin (below normal in 79.5%, 93 of 117), in addition to Factor XI and protein C activity. Patient genotypes were classified based upon the predicted pathogenetic mechanism of disease‐associated mutations, of which most were found in the catalysis/activation, folding, or dimerization regions of the PMM2 enzyme. Two different approaches were used to uncover genotype/phenotype relationships. The first characterized genotype only by the predicted pathogenic mechanisms and uncovered associated changes in biochemical parameters, not apparent using only NPCRS, involving catalysis/activation, dimerization, folding, and no protein variants. The second approach characterized genotype by the predicted pathogenic mechanism and/or individual variants when paired with a subset of severe nonfunctioning variants and uncovered correlations with both NPCRS and biochemical parameters, demonstrating that p.Cys241Ser was associated with milder disease, while p.Val231Met, dimerization, and folding variants with more severe disease. Although determining comprehensive genotype/phenotype relationships has previously proven challenging for PMM2‐CDG, the larger sample size, plus inclusion of biochemical parameters in the current study, has provided new insights into the interplay of genetics with disease. Trial Registration: NCT03173300 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genetics and Personalized Medicine Clinic, Tartu University Hospital, L. Puusepa Street 2, Tartu, Estonia.
- Department of Genetics and Personalized Medicine, Institute of Clinical Medicine, University of Tartu, L. Puusepa Street 2, Tartu, Estonia.
- Children's Clinic, Tartu University Hospital, N. Lunini Street 6, Tartu, Estonia.
- Pediatric Neurology Department and Clinical Biochemistry and Genetics Units, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
- U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain.
- Department of Paediatrics, Metabolic Disease Center, University Hospitals Leuven, Leuven, Belgium.
ORCID-Profile: Sander Pajusalu, Mercedes Serrano, Peter Witters, Anna Cechova, Tomáš Honzik, Andrew C Edmondson, Can Ficicioglu, Rita Barone, Pascale De Lonlay, Claire-Marine Bérat, Sandrine Vuillaumier-Barrot, Christina Lam, Marc C Patterson, Esmeralda Martins, Dulce Quelhas, Jolanta Sykut-Cegielska, Jehan Mousa, Roser Urreizti, Peter McWilliams, Horacio Plotkin, Eva Morava, Katrin Õunap
Förderung
- NINDS NIH HHS
- European Regional Development Fund
- Eesti Teadusagentuur
- Instituto de Salud Carlos III
- Generalitat de Catalunya
- Ministerstvo Zdravotnictví Ceské Republiky
- National Institute of Child Health and Human Development
- National Center for Advancing Translational Sciences
Zitieren
APA
Pajusalu, S., Vals, M. A., Serrano, M., Witters, P., Cechova, A., Honzik, T., Edmondson, A. C., Ficicioglu, C., Barone, R., De Lonlay, P., Bérat, C. M., Vuillaumier-Barrot, S., Lam, C., Patterson, M. C., Janssen, M. C. H., Martins, E., Quelhas, D., Sykut-Cegielska, J., Mousa, J., …, & Õunap, K. (2024). Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2‐CDG. Human Mutation, 2024(1). https://doi.org/10.1155/2024/8813121
Vancouver
Pajusalu S, Vals MA, Serrano M, Witters P, Cechova A, Honzik T, et al. Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2‐CDG. Human Mutation. 2024;2024(1). doi:10.1155/2024/8813121
BibTeX
@article{Pajusalu2024,
author = {Pajusalu, Sander and Vals, Mari-Anne and Serrano, Mercedes and Witters, Peter and Cechova, Anna and Honzik, Tomáš and Edmondson, Andrew C and Ficicioglu, Can and Barone, Rita and De Lonlay, Pascale and Bérat, Claire-Marine and Vuillaumier-Barrot, Sandrine and Lam, Christina and Patterson, Marc C and Janssen, Mirian C H and Martins, Esmeralda and Quelhas, Dulce and Sykut-Cegielska, Jolanta and Mousa, Jehan and Urreizti, Roser and McWilliams, Peter and Vernhes, Frederique and Plotkin, Horacio and Morava, Eva and Õunap, Katrin},
title = {Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2‐CDG},
journal = {Human Mutation},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/8813121}
}
EUVIMED